Last edition
News about "Novo Nordisk"
Novo Nordisk presented new findings from its Wegovy and Cagrilintide trials in obesity management at the ongoing European Association for the Study of Diabetes (EASD) 2025 congress in Vienna, Austria.
Novo Nordisk | 17/09/2025 | By Dineshwori
Novo Nordisk to Cut 9,000 Jobs in Global Restructuring Amid Market Pressures
Novo Nordisk, the Danish pharmaceutical giant behind the weight-loss drug Wegovy and diabetes treatment Ozempic, has announced plans to cut 9,000 jobs worldwide—around 11 to 12 per cent of its workforce—as part of a major restructuring programme.
Novo Nordisk | 10/09/2025 | By Darshana
FDA tightens import controls on obesity drug ingredients amid safety concerns
The Food and Drug Administration (FDA) in the USA has intensified its scrutiny of imports containing GLP-1 drug ingredients, widely used in treatments for weight loss and diabetes, following increasing concerns over safety and quality.
Novo Nordisk | 06/09/2025 | By Darshana | 195
Biopharma Firms See 5.7 Percent Market Cap Drop in Q2 2025: Globaldata
Twenty biopharmaceutical companies have reported a 5.7 percent quarter-on-quarter (QoQ) downturn in their combined market capitalisation from USD 3.9 trillion on 31 March, 2025 to USD 3.7 trillion on 30 June, 2025.
Novo Nordisk | 01/09/2025 | By Dineshwori
Wegovy Outperforms Tirzepatide, Slashes Cardiovascular Risk by 57 Percent
Wegovy showed a significant 29 percent risk reduction for heart attack, stroke and death from any cause compared with Tirzepatide (over an average follow-up of 8.3 months for Wegovy and 8.6 months for Tirzepatide.
Novo Nordisk | 01/09/2025 | By Dineshwori
BioMed X and Novo Nordisk Partner to Advance Oral Peptide Drug Delivery
BioMed X and Novo Nordisk’s partnership aims to address one of the most critical challenges in modern drug development: the efficient oral delivery of therapeutic peptides.
Novo Nordisk | 21/08/2025 | By Dineshwori | 288
Novo Nordisk's Wegovy Approved for Treatment of MASH in Adults with Liver Fibrosis
The US FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis, according to Novo Nordisk.
Novo Nordisk | 16/08/2025 | By Dineshwori | 121
Novo Nordisk Reports 18% H1 Sales Growth, Lowers H2 Outlook for Wegovy and Ozempic
Novo Nordisk has announced its financial results for the first half of 2025, ending June 30, with sales rising 18 percent at constant exchange rates (CER) to DKK 154.9 billion (USD 24.78 billion).
Novo Nordisk | 06/08/2025 | By Dineshwori | 688
Novo Nordisk Appoints Maziar Mike Doustdar as New CEO, Announces Key Organisational Changes
Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen, who will step down as President and Chief Executive Officer of Novo Nordisk next month.
Novo Nordisk | 30/07/2025 | By Dineshwori | 188
Novo Nordisk Expects EC Approval of Alhemo Label Update for Haemophilia in 2 Months
Novo Nordisk has received a positive opinion from EMA’s Committee for Medicinal Products for Human Use (CHMP) for expanded Alhemo use in haemophilia without inhibitors.
Novo Nordisk | 26/07/2025 | By Dineshwori | 191
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy